Back to today’s briefing

Story perspectives

Secretome's New Therapy Trials Aim to Combat Heart Failure

3/26/2025

37 5

Summary

Story summary

Secretome Therapeutics is making strides in heart health by launching a phase 1 trial for STM-01, a groundbreaking neonatal cardiac progenitor cell therapy targeting heart failure with preserved ejection fraction (HFpEF). With fast track designation from the FDA, this trial at The University of Texas and Northwestern Medicine aims to combat inflammation and enhance cardiac function, offering hope to many.

1 of 1

Story summary

Secretome Therapeutics is making strides in heart health by launching a phase 1 trial for STM-01, a groundbreaking neonatal cardiac progenitor cell therapy targeting heart failure with preserved ejection fraction (HFpEF). With fast track designation from the FDA, this trial at The University of Texas and Northwestern Medicine aims to combat inflammation and enhance cardiac function, offering hope to many.